Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | BCHE | P06276 | 15/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tianeptine SCHEMBL2897771 | 1.00 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL3996165 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29930593 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29877330 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29470274 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL49293 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL2894680 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL4262606 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL20338621 | 0.97 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Hydrochloric Acid SCHEMBL22664293 | 0.97 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | claimed |
| WO-2024206520-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240165126-A1 | TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | TONIX PHARMACEUTICALS HOLDING CORP. | 2024-05-23 | — | — | US | claimed |
| CN-110172045-B | Preparation method of intermediate for preparing tianeptine sodium | 甘肃皓天医药科技有限责任公司 | 2023-05-12 | — | — | CN | claimed |
| US-11617757-B2 | Dietary supplement | MORRISETTE JAMES PETER (US) | 2023-04-04 | — | — | US | claimed |
| US-11596640-B2 | Dietary supplement | MORRISSETTE JAMES PETER (US) | 2023-03-07 | — | — | US | claimed |
| US-11590143-B2 | Dietary supplement | MORRISSETTE JAMES PETER (US) | 2023-02-28 | — | — | US | claimed |
| US-11590144-B2 | Dietary supplement | MORRISSETTE JAMES PETER (US) | 2023-02-28 | — | — | US | claimed |
| WO-2022197719-A1 | TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-09-22 | — | — | WO | claimed |
| US-20220211721-A1 | DIETARY SUPPLEMENT | MORRISSETTE JAMES PETER (US) | 2022-07-07 | — | — | US | claimed |
| US-8367656-B2 | Polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide used to treat depressive disorders, irritable bowel syndrome, attention deficit hyperactivity disorder, asthma | JANSSEN BIOTECH, INC. (US) | 2013-02-05 | — | — | US | claimed |
| EP-2367806-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 7-((3-CHLORO-6-METHYL-5,5-DIOXO-6,11-DIHYDRODIBENZO(C,F)(1,2) THIAZEPIN-11-YL)AMINO)HEPTANOATE | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2011-09-28 | — | — | EP | claimed |
| WO-2010070667-A2 | NOVEL PROCESS FOR THE PREPARATION OF 7-((3-CHLORO-6-METHYL-5,5-DIOXO-6,11-DIHYDRODIBENZO(C,F)(1,2) THIAZEPIN-11-YL)AMINO)HEPTANOATE | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2010-06-24 | — | — | WO | claimed |
| EP-2137157-A1 | POLYMORPHS OF 7-[(3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE AND METHODS OF MAKING AND USING THE SAME | Transform Pharmaceuticals, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008109577-A1 | POLYMORPHS OF 7-[(3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080221081-A1 | POLYMORPHS OF 7-[(3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE AND METHODS OF MAKING AND USING THE SAME | JANSSEN BIOTECH, INC. | 2008-09-11 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| CN-1116029-C | Matrix table allowing prolonged release of sodium salt of tianeptine after administration by oral route | SEVIL LAB (FR) | 2003-07-30 | — | — | CN | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1168792-A | Matrix table allowing prolonged release of sodium salt of tianeptine after administration by oral route | ADIR (FR) | 1997-12-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221081-A1 | POLYMORPHS OF 7-[(3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE AND METHODS OF MAKING AND USING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6, CYP2S1 | NR1I2 721/4885OPRM1 497/4885DRD3 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.